A practical reference on albumin binding: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-01. Anything still debated is marked as such rather than presented as settled.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
=== PlayStation 3 version === While the Windows and Xbox 360 versions of The Orange Box were developed and published by Valve, the development of the PlayStation 3 port was outsourced to the Electronic Arts studio EA UK. In an interview with Edge magazine before the game's release, Valve co-founder Gabe Newell commented, "I think the people who have The Orange Box on the PS3 are going to be happy with their game experience. We've done the PC and 360 versions here and EA has a team doing the PS3 version – and they'll make the PS3 version a good product; EA got the job done in putting a lot of people with PS3 experience on the project. But I think it's harder to get it to the same standard as the 360 and PC versions". Despite this, he noted that Valve will probably handle PlayStation 3 versions of its products in the future.
A theoretical prediction estimated this to be −80‰ to −95‰ for steranes, −90‰ to −95‰ for hopanes, and −70‰ to −95‰ for typical cycloparaffins at 0−100°C. At the temperature of the oil window and gas window, the equilibrium fractionation between different group of organic molecules is relatively small, as compared with large primary signals. The study of hydrogen isotopes of fossil fuels has been applied as proxies and tools in the following aspects:
The great beneficiary was the PSOE, which led the campaign in favor of the "YES" vote and from then on became the hegemonic political force in Andalusia. The setback suffered by the UCD in Andalusia was added to the defeat in the municipal and regional elections in Catalonia and the Basque Country. To this was added the worsening of the economic situation as a result of the "second oil crisis" of 1979 (the number of unemployed exceeded one million), the resurgence of ETA's actions which in 1979 and 1980 marked the peak of its activity (174 dead in attacks perpetrated by ETA in those two years, a good part of them military), the growing citizen "disenchantment", etc. All this accentuated the political differences between the groups that made up UCD on various issues which opened a government crisis in mid-April 1980 that resulted in the formation of a new one whose "strong man" was the president's friend, Fernando Abril Martorell. Felipe González then presented a motion of censure against Suárez, which although he did not succeed in getting it through made him the highest-rated political leader in the polls, unseating Adolfo Suárez for the first time, and the PSOE became ahead of UCD in voting intentions. Suárez emerged very weakened from the Socialist motion of censure, which provoked a second crisis in his government in September 1980, which resulted in the departure of the former "strong man" Fernando Abril Martorell. However, the Christian-Democratic sector was not satisfied and started "a full-fledged rebellion".
== Laboratory == biochemistry Arterial blood gas (ABG) Complete blood count (CBC) Comprehensive metabolic panel (CMP) (including CHEM-7) coagulation tests C-reactive protein Erythrocyte sedimentation rate (ESR) FibroTest urea breath test urinalysis Agostini's reaction cytogenetics and Molecular Genetics Genetic testing immunology autoantibodies microbiology blood culture mantoux test sputum culture stool culture urine culture Where available ICD-11, where not ICD-10 codes are listed. See also: https://en.m.wikipedia.org/wiki/Category:Blood_tests and Blood test,
Sources: en.wikipedia.org
== Clinical applications == Clinical application is extremely important to consider when looking at the efficacy of artificial cartilage. The recent clinical approaches for cartilage regeneration in Osteoarthritis treatment is described below.
Protein import into mitochondria Hundreds of proteins encoded by the nucleus are required for mitochondrial metabolism, growth, division, and partitioning to daughter cells, and all of these proteins must be imported into the organelle. Translocase of the outer membrane (TOM) and translocase of the inner membrane (TIM) mediate the import of proteins into the mitochondrion. The translocase of the outer membrane (TOM) sorts proteins via several mechanisms either directly to the outer membrane, the intermembrane space, or the translocase of the inner membrane (TIM). Then, generally, the TIM23 machinery mediates protein translocation into the matrix and the TIM22 machinery mediates insertion into the inner membrane. Fatty acids import into mitochondria (Carnitine Shuttle System) Carnitine-acylcarnitine translocase (CACT) catalyzes both unidirectional transport of carnitine and carnitine/acylcarnitine exchange in the inner mitochondrial membrane, allowing the import of long-chain fatty acids into the mitochondria where they are oxidized by the β-oxidation pathway. The mitochondrial membrane is impermeable to long-chain fatty acids, hence the need for this translocation.
== French interlude and the Bourbon restoration == King Ferdinand was unable to consolidate his power. In 1806, faced with a French invasion by Napoleon Bonaparte's troops, he again had to take refuge in Palermo under the protection of the British navy. The Kingdom of Naples was entrusted by Napoleon to older brother Joseph Bonaparte. Numerous revolts did not mar in the continental Mezzogiorno, such as in Calabria, where the Calabrian Insurrection broke out, carried out by brigands, peasants and army stragglers, supported by British military units. To tame the three year long revolt, Napoleon committed two of the best French generals, André Masséna and Jean Maximilien Lamarque, who employed ruthless means, such as reprisal against entire villages that supported the brigands, as in the massacre of Lauria, perpetrated by Massena's soldiers. In spite of this, Napoleonic rule drove social and economic innovations and upheavals: on 2 August 1806, Joseph Bonaparte decreed the end of feudalism. He abolished baronial jurisdictions, feudal-like personal benefits, and prohibitory rights, i.e., monopolies on specific productive activities. Lands and property were put into liquidation and opened for commercial exploitation by the French government. These were purchased by members of the agrarian bourgeoisie, which was gaining political clout.
=== Oral GLP-1 Semaglutide Generic === SCD has been developing an oral generic version of semaglutide, the active ingredient in Novo Nordisk's Wegovy and Ozempic. In January 2026, SCD signed a partnership agreement with Daiichi Sankyo Espha, a subsidiary of Japan's Daiichi Sankyo, for the exclusive sale of oral semaglutide generics in Japan. Some industry observers and analysts have questioned the company's public statements regarding this product. A commentary published by the Korea Biomedical Review in July 2025 noted that SCD's claims of a potential 2026 market launch for its oral semaglutide generic appeared to overstate the company's regulatory position, given that secondary patents on semaglutide formulations are widely expected to remain in force until at least 2031 in most major markets.
=== Category:EC 1.2 (act on the aldehyde or oxo group of donors) === Category:EC 1.2.1 (with NAD+ or NADP+ as acceptor) Acetaldehyde dehydrogenase EC 1.2.1.10 Glyceraldehyde 3-phosphate dehydrogenase EC 1.2.1.12 Pyruvate dehydrogenase EC 1.2.1.51 Category:EC 1.2.4 Oxoglutarate dehydrogenase EC 1.2.4.2
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.